Biovectra Begins Construction of mRNA Vaccine Biomanufacturing Center
Includes a 36,000-square-foot addition to Charlottetown location
Biovectra, a Canadian contract development and manufacturing organization (CDMO), broke ground on a facility that will manufacture mRNA vaccines and therapeutics, beginning in 2023.
The company’s mRNA Vaccine and Biomanufacturing Center is expected to add 36,000 square feet to its current Charlottetown (located in the Canadian province of Prince Edward Island) campus, and, when operational, the current good manufacturing practice (cGMP) facility will be capable of producing 160 million doses of mRNA vaccines and fill-finish 70 million final vaccine doses per year for commercial distribution.
The CDMO previously announced its $79.6 million expansion of its business to produce mRNA vaccines and therapeutics, with the government of Canada contributing $39.8 million through the Strategic Innovation Fund and a $10 million investment from the Province of Prince Edward Island back in November 2021. The deal is creating 125 new highly skilled jobs and 220 co-op placements in both Prince Edward Island and Nova Scotia.
“As a Canadian company, Biovectra is honored to help our country face future pandemics, while also creating the versatile technology platforms that can help clients deliver the treatments that will become the next generation of patient care,” says Oliver Technow, Biovectra’s CEO.
Understanding the FDA's Exemption for DSCSA Compliance
November 12th 2024In the quest for achieving full traceability, the exemption applies to certain trading partners under the Act, and postpones enforcement of final compliance requirements while acknowledging progress and ongoing challenges.
